• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不稳定型冠状动脉疾病和急性心肌梗死患者血浆中纤溶酶原激活物抑制剂和组织纤溶酶原激活物水平的昼夜波动。

Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.

作者信息

Huber K, Rosc D, Resch I, Schuster E, Glogar D H, Kaindl F, Binder B R

机构信息

Department of Cardiology, University of Vienna, Austria.

出版信息

Thromb Haemost. 1988 Dec 22;60(3):372-6.

PMID:3149044
Abstract

A decrease in the fibrinolytic potential, mainly due to an elevation of plasminogen activator inhibitor (PAI), has been described in patients with stable coronary artery disease and a previous myocardial infarction. We investigated plasma levels of PAI and tissue plasminogen activator (t-PA) and their possible circadian variations in patients with unstable coronary artery disease (CAD). Sixty-three patients were studied for at least 2 consecutive days during their stay at the coronary care unit (CCU). Diurnal plasma fluctuations in PAI and t-PA and onset of further myocardial ischemic episodes were monitored. As controls we used 22 age-matched patients submitted to the clinic because of non cardiac chest pain or valvular disease who revealed no evidence of CAD. PAI levels were significantly elevated in patients with unstable CAD (p less than 0.0001) but were not influenced by the extent of underlying CAD, history of previous myocardial infarction, known risk factors for CAD, or by extent of myocardial damage. The circadian variation of PAI levels with peak values between midnight and 6 A.M. found in controls was still present in patients but at a higher level. Preservation of circadian pattern in PAI plasma levels despite myocardial ischemic attacks indicates that elevation of PAI is rather not caused by a reactive phenomenon. On the other hand, elevated PAI levels and episodes of severe myocardial ischemia exhibiting a median time of onset at 10 A.M. seem to be closely related.

摘要

在稳定型冠状动脉疾病和既往有心肌梗死的患者中,已发现纤溶潜能降低,主要原因是纤溶酶原激活物抑制剂(PAI)升高。我们研究了不稳定型冠状动脉疾病(CAD)患者血浆中PAI和组织纤溶酶原激活物(t-PA)的水平及其可能的昼夜变化。63例患者在冠心病监护病房(CCU)住院期间连续至少2天接受研究。监测PAI和t-PA的昼夜血浆波动以及进一步心肌缺血发作的发生情况。作为对照,我们使用了22例因非心脏性胸痛或瓣膜疾病就诊于门诊的年龄匹配患者,这些患者未发现CAD证据。不稳定型CAD患者的PAI水平显著升高(p<0.0001),但不受潜在CAD的严重程度、既往心肌梗死病史、已知CAD危险因素或心肌损伤程度的影响。对照组中PAI水平在午夜至上午6点之间达到峰值的昼夜变化在患者中仍然存在,但水平更高。尽管发生心肌缺血发作,但PAI血浆水平仍保持昼夜节律模式,这表明PAI升高并非由反应性现象引起。另一方面,PAI水平升高与严重心肌缺血发作似乎密切相关,严重心肌缺血发作的中位发病时间为上午10点。

相似文献

1
Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.不稳定型冠状动脉疾病和急性心肌梗死患者血浆中纤溶酶原激活物抑制剂和组织纤溶酶原激活物水平的昼夜波动。
Thromb Haemost. 1988 Dec 22;60(3):372-6.
2
Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.冠心病男性患者体内的纤溶酶原激活物及纤溶酶原激活物抑制剂活性
J Lab Clin Med. 1989 Jan;113(1):88-93.
3
Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.轻度高同型半胱氨酸血症与ST段抬高型心肌梗死后患者纤溶活性降低有关。
Thromb Res. 2007;119(3):331-6. doi: 10.1016/j.thromres.2006.02.011. Epub 2006 Apr 17.
4
Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).组织型纤溶酶原激活物(t-PA)及其快速作用抑制剂(PAI-1)血液中的日间波动。
Thromb Haemost. 1988 Apr 8;59(2):329-32.
5
[Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].[冠状动脉疾病患者纤溶酶原激活物抑制剂活性增加导致纤溶能力下降]
Helv Chir Acta. 1992 Jan;58(4):503-8.
6
Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.不稳定型心绞痛患者的透壁纤维蛋白溶解活性
Coron Artery Dis. 1996 Jan;7(1):45-9.
7
Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients.老年心肌梗死患者血浆组织型纤溶酶原激活物及其抑制剂水平的变化
Chin Med J (Engl). 1990 Jul;103(7):541-5.
8
[Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].[心肌梗死及其他冠心病危险因素患者的纤溶系统]
Sangre (Barc). 1994 Apr;39(2):111-6.
9
A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.经皮腔内冠状动脉成形术成功后,纤溶酶原激活物抑制剂-1活性降低与冠状动脉再狭窄风险显著降低相关。
Thromb Haemost. 1992 Feb 3;67(2):209-13.
10
Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.杂合子家族性高胆固醇血症心肌梗死年轻幸存者的纤溶参数与胰岛素抵抗
Wien Klin Wochenschr. 2001 Feb 15;113(3-4):113-8.

引用本文的文献

1
The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies.凝血系统在外周动脉疾病中的作用:与动脉壁及其血管微环境的相互作用以及对合理治疗的影响。
Int J Mol Sci. 2022 Nov 29;23(23):14914. doi: 10.3390/ijms232314914.
2
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.2型糖尿病合并冠状动脉疾病患者纤溶酶原激活物抑制剂1日间波动模式的改变:与血浆胰岛素持续升高、胰岛素抵抗增加及腹部肥胖密切相关。
Int J Endocrinol. 2015;2015:390185. doi: 10.1155/2015/390185. Epub 2015 May 18.
3
Dietary fat differentially influences the lipids storage on the adipose tissue in metabolic syndrome patients.膳食脂肪对代谢综合征患者脂肪组织中脂质储存的影响存在差异。
Eur J Nutr. 2014;53(2):617-26. doi: 10.1007/s00394-013-0570-2. Epub 2013 Aug 7.
4
Circadian patterns of ST elevation myocardial infarction in the new millennium.新千年中ST段抬高型心肌梗死的昼夜节律模式。
Clin Med Res. 2013 Jun;11(2):66-72. doi: 10.3121/cmr.2013.1120. Epub 2013 Apr 11.
5
Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.血管紧张素转换酶抑制剂对血栓形成介质的影响:潜在的临床意义。
J Thromb Thrombolysis. 2003 Jun;15(3):217-25. doi: 10.1023/B:THRO.0000011379.68077.64.
6
Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.1型纤溶酶原激活物抑制剂(第二部分):在溶栓治疗失败中的作用。PAI-1抵抗作为新型纤溶药物的潜在益处。
J Thromb Thrombolysis. 2001 May;11(3):195-202. doi: 10.1023/a:1011952602122.
7
Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.1型纤溶酶原激活物抑制剂(第一部分):基本机制、调节及其在血栓栓塞性疾病中的作用
J Thromb Thrombolysis. 2001 May;11(3):183-93. doi: 10.1023/a:1011955018052.
8
Effect of a Change in the Sleep/Wake Cycle on the Diurnal Variation of Fibrinolytic Parameters.睡眠/觉醒周期变化对纤溶参数昼夜变化的影响。
J Thromb Thrombolysis. 1998 May;5(2):165-168. doi: 10.1023/A:1008838330924.
9
Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.纤溶酶原激活物抑制剂:糖尿病患者心肌梗死的一个危险因素。
Br Heart J. 1993 Mar;69(3):228-32. doi: 10.1136/hrt.69.3.228.
10
Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.缺血性心脏病男性患者体内组织型纤溶酶原激活物及其抑制剂、血管性血友病因子抗原和前列环素刺激因子的昼夜变化。
Br Heart J. 1993 Feb;69(2):121-4. doi: 10.1136/hrt.69.2.121.